Clinical observation of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum BNP level

Abstract

Objective To investigate the clinical efficacy of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum B-type natriuretic peptide(BNP). Methods From December 2017 to February 2019, 102 patients with heart failure admitted to Lyucheng Cardiovascular Hospital of Zhejiang Province were selected and divided into control group and treatment group according to random number table method, with 51 cases in each group.The control group was treated with routine treatment, while the treatment group was treated with sakubattral and valsartan sodium tablets on the basis of routine treatment.Both two groups were treated for 12 weeks.The heart function[including left ventricular ejection fraction(LVEF), cardiac output per stroke(SV) and left ventricular end-diastolic diameter(LVEDD)], serum BNP, 6-minute walking distance(6MWD) and quality of life were compared between the two groups before and after treatment. Results The total effective rate of the treatment group was 94.12%(48/51), which was higher than 72.55%(37/51) of the control group, the difference was statistically significant(χ2=8.541, P<0.05). After treatment, the LVEF[(60.28±6.97)%] and SV[(78.91±4.23)mL] in the treatment group were higher than those in the control group[(52.31±4.56)% and (71.35±6.74)mL], while the LVEDD in the trentment group [(54.89±5.26)mm]was lower than that in the control group[(61.74±4.80)mm], the differences were statistically significant(t=6.834, 6.785, 6.870, all P<0.05). After treatment, the serum BNP level in the treatment group[(164.32±14.39)ng/L] was lower than that in the control group[(248.96±23.15)ng/L], while the 6MWD in the trentment group [(353.27±42.26)m] was higher than that in the control group[(273.21±34.47)m], the differences were statistically significant (t=22.175, 10.484, all P<0.05). After treatment, the MLHFQ score in the treatment group[(27.83±5.41)points] was lower than that in the control group[(41.98±7.64)points], the difference was statistically significant(t=10.794, P<0.05). Conclusion Sakubattral and valsartan sodium tablets has good clinical efficacy in treating heart failure, it can improve cardiac function and reduce serum BNP level, which is worthy of clinical application. Key words: Heart Failure; Sakubattral and valsartan sodium tablets; Heart function tests; Stroke volume; Natriuretic peptide, brain; Quality of Life